This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Soliris
  • /
  • Safety and Efficacy of Eculizumab in Refractory Ge...
Clinical trial

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Read time: 2 mins
Last updated:1st Dec 2013
Identifier: NCT01997229

The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.

Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)
Enrollment: 125
Study Start Date: December 2013
Study Completion Date: June 2016
Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)

- Experimental:
- Placebo Comparator: Placebo 

Category Value
Date last updated at source 2017-03-01
Study type(s) Interventional
Expected enrolment 125
Study start date 2013-12-01
Estimated primary completion date 2016-02-01

View full details